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RESUMEN 
Los bloqueantes de los canales de calcio (BCC) son un grupo de drogas con estructuras 
químicas heterogéneas,  entre ellas verapamil, ditiazen y dihidropiridinas. Introducidas en la 
medicina clínica en el año de 1960, son drogas de prescripción frecuente en el tratamiento de los 
desordenes cardiovascular. Los bloqueantes de los canales de calcio son ampliamente utilizados 
en clínica en razón de que inducen vasodilatación arterial  inhibiendo los canales voltaje 
dependientes del calcio del músculo cardiaco y del músculo liso vascular, modificando así  la 
concentración de calcio intracelular fomentando de esa forma la relajación muscular. 
Hipertensión, diabetes, fibrilación auricular, demencia multiinfarto, enfermedad de alzehimer y 
la isquemia cerebral son algunas nuevas indicaciones en investigación para el uso de 
bloqueantes de los canales de calcio. De nuestra revisión se desprende que los efectos atribuidos 
a los BCC en la función cognitiva se ubican todavía en el terreno de la investigación. Trabajos 
futuros aportarán claridad sobre el tema. 
Palabras Clave: Hipertensión arterial, Función cognitiva,   Bloqueantes de los canales de 
calcio, Calcio antagonistas, Terapia antihipertensiva.  
ABSTRACT 
As a group, verapamil, diltiazem and dihydropyridines are commonly named calcium channel 
blockers. Introduced into clinical medicine in the 1960s, they are among the most frequently 
prescribed drugs for the treatment of cardiovascular diseases. All calcium channel blockers that 
have been approved for clinical use induce vasodilation and lowering blood pressure by 
inhibiting the voltage-dependent calcium channels in vascular smooth muscle at significantly 
lower concentrations than are required to interfere with the release of intracellular calcium or to 
block receptor-operated calcium channels. They relax arterial smooth muscle and have little or 
not effect on most venous beds and hence do not affect cardiac preload. In addition to their 
proved cardiovascular effects, preclinical and clinical evidence shows that calcium channel 
blockers may be useful in the treatment of diverse central nervous system disorders such as 
cerebral ischemia, epilepsy, depression and dementia. Hypertension, diabetes, smoking and 
atrial fibrillation are well-recognized risk factors for stroke and multiinfarct dementia which 
may develop to the clinical diagnosis of dementia know as Alzheimer disease. An acquired 
deficit in memory function, problem solving orientation, and abstraction, decreases the capacity 
of an individual to function in an independent manner and are major components of diseases 
related to dementia. In this context, the use of calcium channel blockers to treat hypertensive 
patients and its relation to cognitive function is reviewed in an attempt for elucidate any positive 
or negative connection between high blood pressure, calcium channel blocker treatment and 
cognitive function. 
Key Words: Arterial blood pressure, Cognitive function, Calcium–channel blockers, 
Antihypertensive therapy. 
INTRODUCTION 
Calcium channel blockers were introduced into clinical medicine in the 1960s and are among 
the most frequently used and prescribed drugs for the treatment and management of 
cardiovascular diseases (Freher et al., 1999). According to the common view, their mechanism 
of action is based on an inhibition of the smooth muscle L-type calcium current, thus decreasing 
intracellular calcium concentration and inducing smooth muscular relaxation (Dhein et al., 
1999). These groups of drug have proved to be effective in patients with hypertension, angina 
pectoris and cardiac arrhythmias and they may be beneficial for some patients with migraine, 
preterm labor, esophageal spasm and bipolar disorders (Abernethy and Schwartz, 1999). The 
first clinically available calcium–channel blocker, namely verapamil, is a congener of 
papaverine. Many other calcium–channel blockers are now available and have a wide range of 
structures. The largest group, which includes amlodipine, fenoldipine, isradipine, nicardipine 
and nifedipine, is called dihydropyridines (Hoffman and Carruthers, 2000). 
L – TYPE CALCIUM CHANNELS 
Voltage–sensitive calcium channels belong to a family of homologous proteins that also 
includes channels for Na
+
 and K
+
. These channels contain domains of homologous sequence 
that are arranged in tandem within a single large subunit (Na
+
 and Ca
2+
) or multiple smaller 
subunits with homologous sequences (K
+
 channels). These domains or subunits contain several 
hydrophobic regions that span the membrane and outline an internal pore (Schwartz et al., 
1988). All calcium channel antagonists bind to the a1c subunit of the L-type calcium channel, 
which is the main pore-forming unit of the channel. This subunit is associated with a disulfide-
linked a2d subunit and an intracellular b subunit (Abernethy and Schwartz, 1999). 
Regulation of the L-type channels may differ in different types of cells. In cardiac myocites, 
for example, these channels are activated by catecholamines and other stimuli that activate 
adenylyl cyclase or cyclic adenosine monophosphate-dependent protein kinase (Tsien et al., 
1972; Reuter and Scholz, 1977; Kameyama et al., 1985). On the other hand, in vascular and 
visceral smooth muscle beds, these stimuli can activate, inhibit or have no effect on L-type 
calcium channels, depending on the experimental conditions (Mitra and Morad., 1985; 
Droogmans et al., 1987). Additionally, L-type calcium channels are also activated by endothelin 
(Goto et al., 1989), angiotensin II (Ohya and Sperelakis, 1991) and the a1-adrenergic system 
(Nelson et al., 1988). 
CLINICAL PHARMACOLOGY 
Today, despite of the great number of calcium channel blockers synthesized, only nine of 
them are currently available for clinical use in the United States for the treatment of 
hypertension, angina pectoris and supraventricular arrhythmias. In this context, long-term 
treatment with calcium channel blockers is by oral administration. Only diltiazem, nicardipine 
and verapamil are available in intravenous formulations, and nimodipine is approved for short-
term use in patients with subarachnoid hemorrhage (Abernethy and Schwartz, 1999). 
Pharmacokinetics 
Although the absorption of these agents is nearly complete after oral administration, their 
bioavailability is reduced, in some cases markedly, because of first-pass metabolism in the 
intestinal wall and liver (Kolars et al., 1992). All these drugs are metabolized to less active 
metabolites in the liver by oxidative pathways, predominantly by cytochrome P-450 CYP3A, 
and to a lesser extent by others isoenzymes which belongs to this superfamily (Pichard et al., 
1990; Guengerich et al., 1991; Kroemer et al., 1993). The effects of these drugs are evident 
within 30 to 60 minutes of an oral dose. All these agents are bound to plasma proteins to a 
significant extent ranged between 70–99%; their elimination half-lives range from 1.3 to 5 
hours. During repeated oral administration, bioavailability and half-life may increase because of 
saturation of hepatic metabolism. All calcium channel blockers with the exception of diltiazem 
and nifedipine, are administered as racemic mixtures, with one active and one inactive 
stereoisomer with respect to blockade of L-type calcium channels (Abernethy and Schwartz, 
1988). Hepatic biotransformation of calcium channel blockers such as verapamil may be greater 
in women than men (Schwartz et al., 1994). 
Pharmacodynamics 
All calcium channel blockers that have been approved for clinical use induce vasodilation 
and lowering blood pressure. There are some differences in the relative potency as vasodilators 
among these drugs, with nifedipine been considered the most potent of the dihydropyridines, 
and verapamil, diltiazem and bepridil having less potency (Abernethy and Schwartz, 1999). 
Calcium channel blockers inhibit the voltage-dependent calcium channels in vascular smooth 
muscle at significantly lower concentrations than are required to interfere with the release of 
intracellular calcium or to block receptor-operated calcium channels. The calcium channel 
blockers relax arterial smooth muscle, but they have little effect on most venous beds and hence 
do not affect cardiac preload (Murad, 1996). All classes of calcium channel blockers depress 
sinus-node activity and slow atrioventricular conduction, yet only verapamil and diltiazem delay 
atrioventricular conduction or cause sinus-node depression at doses used clinically. 
Additionally, all calcium channel blockers produce concentration-dependent decreases in 
myocardial contractility in vitro, but only verapamil and diltiazem do so in vivo (Abernethy and 
Schwartz, 1999), (table 1). 
Table 1: Pharmacokinetic profile of L-type calcium channel blockers 
  Verapamil Diltiazem Nifedipine Amlodipine Lacidipine Nitrendipine Felodipine 
Oral absorption (%) > 90 > 90 > 90 > 95 > 90 80–90 > 90 
Bioavailability (%) 10–30 30–60 30–60 52–88 30–60 20 20 
Binding to Plasma 
Protein (%) 
> 90 > 90 > 90 99 > 90 > 90 99 
t-max (hours) 1–2 1–2 1–2 6–12 1–3 1–2 2–4 
Half life (hours) 3–7 3–6 2–3 35–50 8 8 11–16 
Hepatic metabolism +++ +++ +++ +++ +++ +++ +++ 
Active metabolites Yes Yes Yes No No ? Yes 
 
CLINICAL USES AND SOME CONTROVERSIES OF CALCIUM CHANNEL 
BLOCKERS 
Hypertension 
Essential hypertension include a range of different phenotypes and results from genetic 
modifications and the interactions of various risk factors, comorbid diseases, and target organ 
damage which are frequently associated with cardiovascular damage or cerebrovascular and 
renal diseases (Kurchnir, 1999). A large number of clinical trials have demonstrated the benefits 
of antihypertensive therapy. Such trials indicate that the relative risks of stroke, coronary artery 
disease and congestive heart failure are decreased in a significant way using diuretics, b-
blockers and calcium channel blockers as antihypertensive drugs treatment (Kurchnir, 1999). In 
a European Trial, treatment with nitrendipine decreased the death rate from myocardial 
infarction by 56%, fatal and nonfatal cardiovascular end-point by 31%, and stroke by 42% 
(Staessen et al., 1997). From the point of view of the large number of clinical trials, it is 
considered that protective effects against cardiovascular events are also exerted by other long-
acting dihydropyridines (Gong et al., 1996; Hansson et al., 1998). As pointed out by Kuschnir 
(1999), the impact of calcium channel blockers on the cardiovascular system can be summarized 
as follows: a) favorable haemodynamic changes, which include increased diastolic and systolic 
function and improved peripheral circulation, both at rest and during exercise, and increased 
coronary flow reserve (through a vasodilator effect), b) regression of left ventricular 
hypertrophy and vascular hypertrophy (regression in cardiac and vascular remodeling), and c) 
potential antiatherogenic effects. 
Renal protective effects 
An increased attention has been focused on the importance of therapeutic interventions in 
addition to effective blood pressure control, aiming at renal protection. In this regard, calcium 
channel blockers are effective antihypertensive agents for treating hypertensive patients with 
chronic renal impairment, but they have not been studied as intensively as angiotensin 
converting enzyme inhibitors in relation to their ability to slow the progression of renal 
insufficiency independently of their blood pressure lowering effects. There are possible 
mechanisms other than reduction of intraglomerular capillary pressure whereby calcium 
antagonists could delay the progression of chronic renal failure, including reduction of renal 
hypertrophy, attenuation of the mitogenic effects of growth factors, reduction of the metabolic 
activity of remnant kidneys, and modulation of macromolecular traffic across and entrapment in 
the mesangium (Giacheli, 1999). 
Diabetic hypertensive patient 
Calcium channel blockers can be used to treat hypertension in patients with diabetes mellitus 
because they do not affect lipid nor glucose metabolism, or renal function (National High Blood 
Pressure Education Program Working Group, 1994). Angiotensin converting enzyme inhibitors 
slow the progression of diabetic nephropathy and recent trials have linked calcium channel 
blockers with adverse cardiovascular events in hypertensive patients with diabetes (Preston, 
1999). It is worthy to mention that calcium channel blockers such as verapamil and diltiazem 
also decrease the excretion of albumin and other proteins, and apparently improve insulin 
sensitivity (Kaplan, 1998). 
Atherosclerosis 
Flekestein (Drugs Ther. Boletin 1994; Flekestein, 1990)
 
pointed out the relationship between 
calcium and the arterial wall in the atherosclerotic process. He showed the presence of calcium 
deposits in a larger proportion in comparison with lipid deposition in using atherosclerotic 
tissue. He also found evidence of the relationship of these deposits with age and its contribution 
to the artheriosclerotic process (hardening of the arteries). This process occurs when calcium 
reacts with elastin. This is called ectopic calcium (Flekestein, 1990), because it is out of its 
natural place like bones and teeth but not in artery walls. 
Considering these findings, Flekestein proposed the use of the calcium channels blockers to 
avoid calcium deposition in the arterial walls. 
Use of calcium channel blockers and the risk of cancer 
The hypothesis that calcium channel blockers may be carcinogenic has been pointed out by 
different authors (Horton, 1996; Pahor et al., 1996
a
; Pahor et al., 1996
b
; Hardell et al., 1996). 
One of the proposed mechanism is that calcium channel blockers inhibit the process called 
apoptosis, in which damaged cells are eliminated (Durham and Walton, 1986; Trump and 
Berezesky, 1995), while another point to the block of transmembranous calcium channels, 
which may cause an intracellular decrease of calcium content in certain tissues (Hardell et al., 
1996). The possibility of increased risk of cancer induced by calcium channel blockers is 
supported by the work of Pahor and coworkers (1996
b
), where they showed that from all 
participants who were taking these drugs, they found a 1.7-fold increased incidence of cancer 
after 4 years of follow-up. However, Olsen and colleagues found no evidences of a tumor-
promoting effect induced by these drugs (Olsen et al., 1997). Although this study is similar in 
the follow-up period to that of Pahor et al (1996b), both are too brief to measure a carcinogenic 
effect, even if the drugs act as tumor promoters. Finally, the authors suggest that studies with 
longer follow-up periods are needed to clarify any potential carcinogenic effect associated to 
these drugs (Olsen et al., 1997). 
UTILITIES AND CONTROVERSIES OF CALCIUM CHANNEL BLOCKERS USED 
TO TREAT HYPERTENSIVE PATIENTS AND ITS RELATION TO COGNITIVE 
FUNCTION 
Controversy - History 
In 1995, some retrospective reports, showed that certain patients treated with short-acting 
calcium antagonists were at increased risk for myocardial infarction and had a higher mortality 
rate compared with patients treated with other cardiovascular drugs (59). Subsequently reports 
attempted to establish a connection between calcium antagonists and disorders as diverse as 
malignancy, parkinsonism, cognitive dysfunction and suicide (60). However, several 
prospective studies have reported that calcium antagonists exert a beneficial effect on morbidity 
and mortality in a variety of cardiovascular disorders such as hypertension, ischemic heart 
disease after myocardial infarction, and congestive heart failure due to dilated cardiomyopathy 
(61). 
Hypertension, aging and memory loss. Remarkable facts and use of calcium channel 
blockers 
Hypertension is an important public health challenge not only in the United States but also 
around the world because of its high prevalence and the concomitant increase in the risk of 
cardiovascular/renal disease. As many as 43 million Americans have hypertension, which is 
defined as a systolic blood pressure (SBP) ž 140 mmHg and or a diastolic blood pressure (DBP) 
ž 90 mmHg and/or taking antihypertensive medications (Burt et al., 1995). Moreover, 
hypertension is the most important modifiable risk factor for coronary heart disease (the leading 
cause of death in the US population), stroke (the third leading cause of death), congestive heart 
failure, end-stage renal disease, and peripheral vascular disease (MacMahon et al., 1990; Kannel 
and Belanger, 1991; Klag et al., 1996; He and Whelton, 1999). 
Prospective studies have repeatedly identified an increasing risk of cardiovascular disease, 
stroke, and renal insufficiency with progressively higher levels of both SBP and DBP 
(MacMahon et al., 1990; Kannel and Belanger, 1991; Klag et al., 1996; He and Whelton, 1999). 
As long as we know, calcium channel blockers have at least 33 years history in the therapy 
of hypertension. However, their potential indications are not limited to cardiovascular diseases. 
Preclinical and clinical evidence is accumulating showing that calcium channel blockers may be 
useful in the treatment of various disorders of the central nervous system (Schuurman and 
Traber, 1994). 
Efficacy of calcium antagonists has been shown in animal models of epilepsy, cerebral 
ischemia, depression, and dementia (Scriabine et al., 1989; Czyrak et al., 1989; De Jonge et al., 
1993). One report showed that brain aging is associated with a reduction or even the loss of 
various functions such as learning and memory capability, diurnal rhythms, social behavior, and 
sensorimotor functions. This was observed not only in humans but also in many animals’ 
species including rodents (Schuurman et al., 1986). Attempts to improve one or more of these 
old age-related deficiencies by pharmacological treatments have not been successful until now. 
However, a number of animal studies suggest that the calcium channel blocker nimodipine may 
be a drug candidate in the treatment of some behavioral symptoms that occur during aging 
(Schuurman and Traber, 1994). 
Thirty years ago “atherosclerosis” was almost synonymous with dementia, now 
“Alzheimer’s disease” is (Hachinski and Munoz, 2000). Most definition of dementia requires 
that the patient be incapable of self-sufficiency. By that time it is too late to do anything except 
provide symptomatic treatment regardless of the etiology of the dementia. The cornerstone of all 
criteria of dementia is memory impairment. This criterion works very well for Alzheimer’s 
disease, where memory loss is an early and constant feature, but it seldom helps in identifying 
individuals with cognitive impairment on a vascular bases (Hachinski and Munoz, 2000). 
Hypertension, diabetes, smoking, and atrial fibrillation are well recognized risk factors for 
stroke and multiinfarct dementia, and also now it appears that they may be risk factors for 
dementia diagnosed clinically as Alzheimer’s disease. Moreover, preliminary evidence suggests 
that treating hypertension may decrease or delay dementia (Hachinski and Munoz, 2000). 
Cognitive impairment, or an acquired deficit in memory function, problem solving, 
orientation, and abstraction, diminishes an individual’s capacity to function independently and 
is a major component of dementing disease (Colsher and Wallace, 1991; Launer et al., 1995). 
As we mentioned above, elevated blood pressure is an established risk factor for stroke 
(MacMahon et al., 1990) and contributes to silent small-vessel disease and white-matter 
hyperintensities seen on neuroimaging (Miller, 1983; Erkinjuntti et al., 1993; Tatamichi et al., 
1994), thus, these cerebral lesions have been associated with cognitive impairment in both 
clinical and population-based studies. 
Taking into account the evidences that elevated blood pressure is also a risk factor for 
vascular dementia (Erkinjuntti et al., 1993), it might be expected that as long as blood pressure 
continues elevated, cognitive impairment in old age patients might be increased (Launer et al., 
1995). The results from cross-sectional studies or clinic-based studies, with a relatively short 
follow-up period are mixed: some suggest that elevated blood pressure may impair cognitive 
function (Wilkie and Eisdorfer, 1971; Wallace et al., 1985; Sands and Meredith, 1992; Starr et 
al., 1993), while others fail to show a convincing relationship between blood pressure levels and 
performance on cognitive tests (Wilkie et al., 1976; Farmer et al., 1987; Elias et al., 1989; 
Scherr et al., 1991). 
In a report from Great Britain, cognitive function was prospectively assessed in a large 
sample of older adults randomized to diuretics, b blockers, or placebo treatments groups to 
investigate the relation between treatments of moderately raised blood pressure and cognition 
(Prince et al., 1996). The analysis of data does not provide any evidence for a cognitive benefit 
from antihypertensive treatment. Even restriction of the analysis to those subjects who had 
completed the study and remained on their randomized medication throughout (therefore, the 
treatment effect on systolic blood pressure was maximal), did not reveal any difference in 
cognitive outcome between the placebo and active treatment groups. However, this result did 
not prove that when hypertension is treated effectively, cognitive effects might not be achieved. 
Finally, the authors concluded that treatment of moderate hypertension with diuretics 
or β blockers was unlikely to influence, for better or worse, subsequent cognitive function 
(Prince et al., 1996). 
In a 15-years longitudinal study of blood pressure and dementia, Skoog and co-workers 
examined a gerontological and geriatric population to investigate the relation between blood 
pressure and the development of dementia. Their conclusion was that there is an association 
between high blood pressure at age 70 and dementia which developed more than 9 years later, 
suggesting that antihypertensive treatment may have remarkably implications in the 
development of dementia and perhaps Alzheimer’s disease. It is worthy to mention that in this 
study despite of the sample size (382 patients) which is considered small, the authors assumed 
that is representative of subjects surviving up to the age of 85, indicating that the finding could 
be generalized to the total population of 85-years-olds, which might not be the case. 
In 1992, the first prospective clinical evidence of possible adverse cognitive effects related to 
a calcium channel blocker aroused (Skinner et al., 1992). In this study when the crossover data 
were ignored and results for the first drug treatment was considered alone, change in 
performance on both digit symbol and Buschke selective reminding tests were worse for 
nifedipine than for atenolol. However, the study has a very narrow window of conclusions 
because: a) their results apply only to nifedipine and atenolol and might not be generalizable to 
other calcium-channel or b-receptor antagonists and b) with the exception of the Buschke 
selective reminding test and the digit symbol test, other tests failed to show any significant 
difference between the two drugs. 
The Honolulu-Asia Aging Study examined the relationship of blood pressure measured in 
midlife to cognitive function measured 25 years later in late life (Launer et al., 1995). They 
found that the risk for reduced cognitive function in very old men progressively increases with 
systolic blood pressure levels measured in midlife 25 ± 1.1 years prior to the measurement of 
cognitive function, suggesting that midlife systolic blood pressure is a significant predictor of 
reduced cognitive function in later life, and that early control of systolic blood pressure levels 
may reduce the risk for cognitive impairment in old age (Launer et al., 1995). 
On the other hand, the Canadian Study of Health and Aging, a prospective study was 
undertaken to examine prospectively the association between the use of calcium channel 
blockers and others antihypertensive drugs and cognitive function (Maxwell et al., 1999). They 
analyzed data from 509 subjects and after some of the died and exclusion of others for different 
reasons the total number of subjects for analysis was reduced to 205, of which only 68 were 
under calcium channel blockers treatment, either as monotherapy or in combination with other 
antihypertensive drug. A decline of 10 in performance on the Modified Mini-Mental State 
(3MS) was considered clinically significant. The authors interpreted their results saying that 
older people taking calcium channel blockers were significantly more likely than those using 
other agents to experience cognitive decline and emphasized the need for further trials to 
examine the associations between calcium channel blockers use, blood pressure and cognitive 
impairment in elderly patients, a statement very cautious from the authors. However and in 
agreement with the analysis made by Dinsdale (1999), in this study the duration of treatment 
was short, the number of subjects was small, the variables analyzed were numerous and the 
confidence limits were wide, therefore, the question asked by Dinsdale (1999), of what might 
those associations be?, still remain unanswered. 
CONCLUSION 
Today, the main clinical indications for calcium channel blockers are in the therapy of 
angina and hypertension in which these drugs are considered highly effective (Opie et al., 
2000), however, their effects on cognitive function still remain a big controversy. There are a 
general agreement of opinions concerning that additional randomized controlled trials are 
needed to clarify this issue. While we wait until the light inside the tunnel is turned on, 
physicians faced with the need to treat hypertension and others related cardiovascular disorders 
in elderly patients, and calcium channel blockers still and will play a remarkably important role 
in the management and prevention of complications of different cardiovascular diseases. 
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